$ELDN News
Last published 2w ago
- 2w agoELDNEledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual MeetingGlobeNewswireTegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treated patients experienced a mean worsening of symptom occurrence
- 2mo agoELDNEledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation SocietyGlobeNewswireIRVINE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced an oral presentation highlighting the long-term safety and efficacy of tegoprubart in
- 2mo agoELDNEledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026GlobeNewswireIND submitted to FDA for Eledon-sponsored, registrational study of tegoprubart in islet cell transplantation for patients with type 1 diabetes First patients enrolled in new investigator-initiated study of
- 3mo agoELDNEledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswireSuccessful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026 Long-term Phase 2 BESTOW data presented at ATC 2026
- 3mo agoVRTXELDNVKTXA Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating UpPR Newswire(American News Group News Commentary) For the millions of people who manage diabetes with daily insulin injections, the holy grail has always been...
- 4mo agoSANAELDNNCELVRTXThe Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho TherapyPR NewswireUSA News Group News Commentary - The most valuable real estate in medicine right now is a living cell. Across diabetes, organ transplant, and the...
- 4mo agoNCELELDNNewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 DiabetesGlobeNewswireZURICH, July 01, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (("NewcelX", NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, announced the successful completion of
- 4mo agoNTRAELDNNatera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant TrialBusiness WireProspera selected as exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay for use in Eledon’s planned Phase 3 trial of tegoprubart in kidney transplantation, expected to initiate in late 2026Natera, Inc.
- 4mo agoELDNEledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with TacrolimusGlobeNewswireTegoprubart-treated patients maintained higher mean eGFR over time, including a statistically significant approximately 12 mL/min/1.73 m² advantage at month 18 versus tacrolimus (74 vs. 61 mL/min/1.73 m²; p<0.05) No
- 5mo agoELDNEledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago MedicineGlobeNewswire– All 12 patients in study (100%) achieved insulin independence, producing their own insulin and no longer requiring exogenous insulin therapy to manage their T1D – All 12 patients also achieved an HbA1c below 6.5%,
- 5mo agoELDNEledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific SessionsGlobeNewswireIRVINE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that updated results from an investigator-initiated trial being conducted at the University of
- 5mo agoELDNNCELNewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 DiabetesGlobeNewswirePre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (("NewcelX", NASDAQ:NCEL), a
- 5mo agoELDNEledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant CongressGlobeNewswireIRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the Company will present new clinical data from its tegoprubart program in patients undergoing
- 6mo agoELDNEledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswire100% insulin independence achieved in 10 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study FDA Orphan Drug designation granted to tegoprubart for the
- 6mo agoELDNNCELNewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026GlobeNewswireNewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long-term value driver
- 6mo agoELDNNCELNewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech ConferenceGlobeNewswireZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (NASDAQ:NCEL),– NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced
- 7mo agoVCELSANALCTXELDNWhy Smart Money Is Shifting From Clinical Data to Manufacturing LinesPR NewswireThe global cell therapy manufacturing market is on track to nearly double, from $7.17 billion in 2026 to over $14 billion by 2035[1]. The science has ...
- 8mo agoELDNEledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago MedicineGlobeNewswire- 12-patient cohort fully enrolled with an average time since transplant of approximately 8 months - 100% insulin independence achieved in 10 patients who are over 4 weeks post-transplant - No signs of graft rejection
- 8mo agoELDNEledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver TransplantationGlobeNewswireIRVINE, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to
- 8mo agoNCELELDNNewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 DiabetesPR NewswireNewcelX Ltd. ("NewcelX") (Nasdaq: NCEL), a clinical-stage company advancing stem-cell-derived therapies for Type 1 Diabetes, today announced a...
- 8mo agoELDNEledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare ConferenceGlobeNewswireIRVINE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, and Steven Perrin, Ph.D., President
- 9mo agoELDNEledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026GlobeNewswireIRVINE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that Steven Perrin, Ph.D., President and Chief Scientific Officer will participate in a fireside
- 9mo agoELDNEledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter SymposiumGlobeNewswireData from eight participants continue to support safety and tolerability profile of tegoprubart Mean eGFR increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months
- 10mo agoELDNEledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 OutlookGlobeNewswirePhase 2 BESTOW trial data evaluating tegoprubart in kidney transplantation showed favorable efficacy, safety and tolerability, supporting advancement into Phase 3 development Reported positive preliminary results from
- 10mo agoNVOELDNVKTXTNDMThe End of Shots? 5 Biotech Stocks Rethinking DiabetesPR NewswireUSA News Group News Commentary – Recent clinical trials achieving 83% insulin independence rates have ignited a dramatic shift in metabolic disease...
- 11mo agoELDNEledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare ConferenceGlobeNewswireIRVINE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer will participate in a fireside chat at
- 11mo agoELDNEledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago MedicineGlobeNewswireIRVINE, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced preliminary results from an investigator-initiated trial conducted at the University of Chicago
- 12mo agoELDNEledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial ResultsGlobeNewswireData from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus Data supports
- 12mo agoELDNEledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireIRVINE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN), today announced the pricing of its underwritten public offering of (i) 15,152,485 shares of its common stock at a
- 1y agoELDNEledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireIRVINE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN), today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu
- 1y agoELDNEledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology's Kidney Week 2025 Annual MeetingGlobeNewswireData from patients who remained on tegoprubart for a year post transplant showed an overall mean 12-month estimated glomerular filtration rate (eGFR) of approximately 69 mL/min/1.73 m² Tegoprubart demonstrated a
- 1y agoELDNEledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation ConferenceGlobeNewswireIRVINE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer will present at the upcoming
- 1y agoELDNEledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual MeetingGlobeNewswireIRVINE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced an oral presentation will be featured at the American Society of Nephrology's upcoming Kidney Week
- 1y agoELDNEledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation AssociationGlobeNewswireIRVINE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that Steve Perrin, Ph.D., President and Chief Scientific Officer, will participate in a plenary
- 1y agoELDNEledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025GlobeNewswireIRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat
- 1y agoELDNEledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial ResultsGlobeNewswireUpdated data from ongoing open-label Phase 1b trial demonstrated a mean 12-month eGFR of approximately 68 mL/min/1.73 m2 post-transplant for patients on tegoprubart Company on track to report topline results from Phase
- 1y agoELDNEledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney TransplantationGlobeNewswireData from patients who remained on tegoprubart for a year showed overall mean 12-month eGFR of approximately 68 mL/min/1.73 m² post-transplant Preliminary iBox data, a key biomarker of kidney function and immunologic
- 1y agoELDNEledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025GlobeNewswireIRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the company will host a conference call and webcast on Wednesday, August 6, 2025 at 4:30 p.m.
- 1y agoELDNUpdated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025GlobeNewswireIRVINE, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for
- 1y agoELDNEledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York CityGlobeNewswireIRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that it will host an R&D Day in New York City on Wednesday, July 9, 2025 beginning at 8:30 am
- 1y agoELDNEledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial ResultsGlobeNewswireOn track to report topline results from Phase 2 BESTOW trial in kidney transplantation in fourth quarter of 2025 Tegoprubart used as a key component of immunosuppression regimen in its second transplant of a
- 1y agoELDNEledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial ResultsGlobeNewswireTegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Announced positive initial data
- 1y agoELDNEledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare ConferenceGlobeNewswireIRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside
- 1y agoELDNEledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a HumanGlobeNewswirePatient treated in procedure, conducted at Mass General Transplant Center and in collaboration with partner eGenesis, was recently released from hospital Investigational therapy tegoprubart targets CD40 ligand (CD40L)
- 1y agoELDNEledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech ConferenceGlobeNewswireIRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, and Steve Perrin, Ph.D., Chief
- 1y agoELDNEledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 OutlookGlobeNewswireCompleted enrollment in Phase 2 BESTOW trial assessing tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Presented updated data on 13
- 1y agoELDNEledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial ResultsGlobeNewswireCompleted enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Announced positive initial data from
- 2y agoELDNEledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation ConferenceGlobeNewswireIRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat
- 2y agoELDNEledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireIRVINE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN), today announced the pricing of its underwritten offering of (i) 18,356,173 shares of its common stock at a price
- 2y agoELDNEledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago MedicineGlobeNewswire- First two out of three subjects treated with tegoprubart as part of immunosuppression regimen to prevent transplant rejection achieved insulin independence and remain insulin free, with glucose control in the normal